Nimbus Group AB (9RN)
Market Open
12 Aug, 06:03
XFRA XFRA Primary €
0. 98
-0.04
-3.6453%
€
30.62M Market Cap
- P/E Ratio
- Div Yield
200 Volume
-0.13 Eps
€ 1.01
Previous Close Want to track 9RN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
9RN trading today lower at €0.98, a decrease of -3.6453% from yesterday's close, completing a monthly decrease of -8.169% or -€0.09. Over the past 12 months, 9RN stock gained 4.4872%.
9RN is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Nimbus Group AB (9RN) FAQ
What is the stock price today?
The current price is €0.98.
On which exchange is it traded?
Nimbus Group AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 9RN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 30.62M.
Has Nimbus Group AB ever had a stock split?
No, there has never been a stock split.
Nimbus Group AB Profile
| Health Care Technology Industry | Healthcare Sector | Mr. Allan Roger Will B.S., M.S. CEO | XFRA Exchange | SE0015407390 ISIN |
| AU Country | - Employees | 19 May 2022 Last Dividend | - Last Split | - IPO Date |
Overview
EBR Systems, Inc., founded in 2003 and headquartered in Sunnyvale, California, specializes in the development of innovative implantable systems for wireless tissue stimulation. The company's groundbreaking technology aims to address and mitigate the complications associated with traditional pacing methods by introducing a leadless, wireless stimulation solution. Its focus is primarily on enhancing cardiac resynchronization therapy (CRT) through the use of proprietary wireless technology, revolutionizing the treatment of heart failure patients by improving patient outcomes and quality of life.
Products and Services
- WiSE Cardiac Resynchronization Therapy System: This system represents a significant advancement in the treatment of heart failure. Unlike traditional CRT devices that require leads to deliver pacing, the WiSE system utilizes EBR Systems, Inc.'s proprietary wireless technology to stimulate the inside of the left ventricle directly. This approach seeks to improve the heart's efficiency while aiming to eliminate the risks and complications associated with lead-based devices, such as placement difficulty, unintended nerve stimulation, dislodgement, extraction, and repositioning. The WiSE system exemplifies EBR Systems, Inc.'s commitment to improving cardiac care through innovation.
Contact Information
Address: 480 Oakmead Parkway, Sunnyvale, CA, United States, 94085
Phone: 408 720 1906
Website: https://ebrsystemsinc.com
